Follow us:

Vaginal Mesh Lawsuit Brings Big Verdict for Injured Plaintiff

Posted on

The Transvaginal Mesh Implant bellwether case against named Defendant C.R. Bard, which began in Charleston, West Virginia on Monday, July 8th , has finally produced a long awaited verdict. The jury returned a verdict on August 15th in favor of the plaintiffs, finding for the plaintiffs on both design defect and failure to warn, and awarding $250,000 in compensatory damages.  The jury also determined that punitive damages were warranted, and returned a punitive damages verdict of $1.75 million.  The second bellwether trial is scheduled to begin this Monday, August 19th.

Although the defense team was quite confident going into the trial, the jury made it quite clear C.R. Bard was in the wrong after having the opportunity to hear plaintiff Donna Cisson’s struggles after being implanted with C.R. Bard’s Avaulta Plus Posterior BioSynthetic Support System in May of 2009. As a result the implant of her Avaulta Plus Posterior BioSynthetic Support System, Cisson has endured both physical and mental pain, sustaining permanent injury along with permanent and substantial physical deformity. Additionally, Cisson had to undergo costly corrective surgeries and her loss of present and future lost wages has amounted to a significant economic loss for her family. Moreover, Cisson has suffered from impaired physical relations with her husband Dan, a co-plaintiff in the case, who himself has suffered a loss of his wife’s consortium and companionship.

The jury also learned that Mrs. Cisson’s life altering injuries caused by her Transvaginal Mesh Implant manifested despite C.R. Bard’s strong assurances to the general public, hospitals and healthcare professionals that the Bard Avaulta Mesh was safe and effective for its intended purpose. But furthermore, those very assurances are what Mrs. Cisson, and most likely the thousands of other innocent women, as well as her healthcare providers relied upon in making the decision to have her implanted with C.R. Bard’s Avaulta Plus Posterior BioSynthetic Support System in the first place. The dangers and risks of these TVM and mesh implants has been discussed in detail over the last few years, but more information and review is still needed.

Perhaps most significantly, the jury determined the conduct of C.R. Bard warranted the verdict including the significant punitive damages. The aforementioned conduct, which has been misleading at best, included a spokesman for Bard informing Bloomberg News that the Avaulta Mesh is a “safe and effective treatment for pelvic organ prolapse when used in accordance with its instructions.” However, and in contrast to, unsealed case documents show that Bard executives were quite aware, and understood, that the plastic resin that makes up the polypropylene mesh material was not designed to be implanted in the human body. That information was contained in a “Material Safety Data Sheet” filed with the federal government by a unit of Chevron Phillips Chemical Company concerning the Marlex Polyproylene Material. Background story found here.

“Do not use this Phillips Sumika Polypropylene Co. material in medical applications involving brief or temporary implantation in the human body or contact with internal body fluids or tissues unless the material has been provided directly from Phillips Sumika Polypropylene Co. under an agreement that expressly acknowledges the contemplated use,” according to the warning.

To make the knowledge and conduct of the C.R. Bard  officials even more suspect, the attorney for the Plaintiff added that in order to protect their supply of this plastic mesh material, (which is not produced for the purpose of and should not be used  in “medical applications involving permanent implantation in the human body or permanent contact with internal body fluids or tissues” ) the Bard officials warned each other in e-mails not to allow the Chevron Philips executives to learn they were using the material in human implants. It would come as no surprise to learn of additional deceitful acts committed by C.R. Bard given the amount of information brought to light by this short lived two-day resulting in the unfortunate mistrial and rescheduling.

The firestorm for the Murray Hill, New Jersey based C.R. Bard is far from over since they still face over 3,600 claims pertaining to their ‘internally highly regarded’ Avaulta Plus Mesh Implants, which have plaintiff alleging cause serious internal damage. Other Transvaginal Mesh Implant makers, including Johnson & Johnson (JNJ), Endo Health Solutions Inc. (ENDP) and Boston Scientific Corp. (BSX) face similar claims of their products degrading and shrinking over time injuring their recipients. American Medical Systmens and Coloplast cases are possibly also facing lawsuits.

Tags: , , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *